Covid19
Conditions
Keywords
ICU, Covid 19, C19, Coronavirus, geko, Deep venous thrombosis, DVT
Brief summary
The primary objectives of this pilot study protocol are to assess safety and feasibility of using the geko™ device in COVID-19. Regarding safety to patients, we will measure the rate of adverse events, primarily local site irritation or discomfort. Feasibility will be measured on the basis of recruitment; ability to enroll sufficient number of patients meeting criteria. Protocol adherence will be observed as the ability to deliver the study intervention to the patients randomized to the treatment arm within the prescribed timeline and ability to complete the course of treatment. Additionally, we plan to measure patient outcomes such as ICU admission and death. The findings of this study have the potential to decrease the complications seen in COVID-19 infections.
Detailed description
On March 11, 2020, a global pandemic was declared by the World Health Organization. A novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified as the cause of the COVID-19 pandemic. SARS-CoV-2 infection has quickly become one of the fastest growing and deadliest diseases to surface due to its high death rate and ability to replicate and spread readily from people without symptoms. Recent evidence indicates that critically ill patients with COVID-19 experience a high risk of blood clots. Deep leg vein blood clots can travel to the lungs and cause severe lung failure and death. The geko™ device is a simple device that increases the return of blood flow from the lower legs and potentially decrease the risk of lung blood clots. Investigators believe the geko™ device may have an important benefit in COVID-19 patients by decreasing the risk of lung clots and decrease the risk of respiratory failure which is often the cause of death in COVID-19 patients. In this study, Investigators plan to study the effect of using the geko™ device in COVID-19 patients and measure patient outcomes such as ICU admission and death. The findings of this study have the potential to decrease the complications seen in COVID-19 infections.
Interventions
DEVICEgeko T3
The device stimulates the peroneal nerve.It will be applied for the entire duration of ICU stay and replaced once every 24 hours.
Sponsors
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Randomized Controlled Trial of 20 participants in each arm.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients who test positive for Covid-19
Exclusion criteria
* Patients who are unlikely to be adherent or cannot tolerate the therapy (self-report) * Prior above or below knee amputation * A history of prior Deep Venous Thrombosis (DVT) or Venous Thromboembolism (VTE), * Those patients being treated with full dose therapeutic anticoagulation. * Patients with pacemakers
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Feasibility of recruitment | Within a two year period | Feasibility will be measured on the basis of recruitment; ability to enroll sufficient number of patients meeting criteria |
| Safety of device: AE | From ICU admission to discharge or death in ICU up to 28 days whichever comes first. | We will measure the rate of adverse events, primarily local site irritation or discomfort |
| Protocol Adherence | From ICU admission to discharge or death in ICU up to 28 days whichever comes first. | We will assess our ability to deliver the study intervention to the patients randomized to the treatment arm within the prescribed timeline and ability to complete the course of treatment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mortality | From date of admission to discharge from ICU or death in hospital assessed up to a 28 days whichever comes first. | The impact of the geko™ device on patient outcomes in critically ill COVID-19 patients. |
| Morbidity | From date of admission to discharge from ICU assessed up to a 28 days whichever comes first. | The impact of the geko™ device on patient outcomes in critically ill COVID-19 patients. |
Countries
Canada
Outcome results
None listed